View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 27, 2020updated 12 Jul 2022 11:39am

Celltrion gets approval to trial antibody-based Covid-19 treatment

Celltrion Group has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to conduct a Phase I clinical trial of its antiviral antibody treatment candidate, CT-P59, against Covid-19.

Celltrion Group has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to conduct a Phase I clinical trial of its antiviral antibody treatment candidate, CT-P59, against Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Celltrion has commenced enrolment of patients with mild symptoms of the disease.

The company discovered CT-P59 as a potential Covid-19 treatment after screening antibody candidates and selecting those with highest potency in neutralising the SARS-CoV-2 virus, including the mutated G-variant strain (D614G variant).

In pre-clinical testing, the drug candidate led to a 100-fold decrease in the viral load of SARS-CoV-2 and also reduced lung inflammation.

The Phase I study is designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59.

Celltrion expects to obtain data from the Phase II and III trials in patients with mild symptoms, the Phase III trial for moderate-to-severe CovidD-19 and the prevention trial, by the end of the year.

For the prevention trial, the company will enrol people who are in close contact with Covid-19 patients and those with no symptoms to investigate if CT-P59 can trigger a neutralising antibody response to prevent the infection.

Celltrion senior executive vice-president Dr Sang Joon Lee said: “We have initiated an in-human global Phase I clinical trial of CT-P59 in mild Covid-19 patients and we plan to conduct further global Phase II and III trials in this patient group.

“In addition, Celltrion plans to combine Phase II and III trials in patients with moderate-to-severe Covid-19 with the prevention clinical trials.

“We are extremely encouraged by the consistent progress we are making in preparation for our CT-P59 clinical trials in various settings, and we remain on track to reach our upcoming milestones.”

In July, the company launched a Phase I trial of CT-P59 in the UK after approval from the Medicines and Healthcare products Regulatory Agency (MHRA).

The company also completed an infusion and initial safety evaluation in the Phase I trial in healthy volunteers in Korea.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena